Grace Centre for Newborn Care, The Children's Hospital at Westmead, Westmead, Australia.
Department of Neonatology, Westmead Hospital, Westmead, Australia.
Cochrane Database Syst Rev. 2023 May 26;5(5):CD012218. doi: 10.1002/14651858.CD012218.pub2.
Neonates who have undergone gastrointestinal surgery are particularly susceptible to infectious complications in the postoperative period. This may be due in part to disruption of the integrity of the gut and its altered intestinal microflora. Lactoferrin is a whey protein found in milk and is an important innate mammalian defence mechanism. Lactoferrin has been reported to have antimicrobial and anti-inflammatory properties. It has also been reported to help establish a healthy gut microflora and aid in the intestinal immune system. Lactoferrin supplementation has been reported to decrease sepsis in preterm infants. There may be a role for lactoferrin to reduce the incidence of sepsis, thus reducing morbidity and mortality and improving enteral feeding in postoperative term neonates.
The primary objective of this review was to evaluate the efficacy of administering lactoferrin on the incidence of sepsis and mortality in term neonates after gastrointestinal surgery. The secondary objective was to assess the impact of administering lactoferrin on time to full enteral feeds, the intestinal microflora, duration of hospital stay, and mortality before discharge in the same population.
The Cochrane Neonatal Information Specialist searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase Ovid, CINAHL, the WHO ICTRP and ClinicalTrials.gov trials registries. The date of the last search was February 2023. There were no restrictions to language, publication year or publication type. We checked references of potentially relevant studies and systematic reviews.
We planned to include randomised controlled trials that studied infants born at 37 or more weeks of gestation who had one or more episodes of gastrointestinal surgery within 28 days of birth, and compared administration of lactoferrin with a placebo.
We used standard Cochrane methodological procedures. We planned to use the GRADE approach to assess the certainty of evidence for each outcome.
We identified no published randomised controlled studies that assessed the efficacy of lactoferrin for the postoperative management of term neonates following gastrointestinal surgery.
AUTHORS' CONCLUSIONS: There is currently no evidence available from randomised controlled trials to show whether lactoferrin is effective or ineffective for the postoperative management of term neonates after gastrointestinal surgery. There is a need for randomised controlled trials to be performed to assess the role of lactoferrin in this setting.
接受过胃肠道手术的新生儿在术后特别容易发生感染并发症。这可能部分归因于肠道完整性的破坏和其改变的肠道微生物群。乳铁蛋白是乳清蛋白中的一种,是一种重要的哺乳动物先天防御机制。乳铁蛋白具有抗菌和抗炎特性。它还有助于建立健康的肠道微生物群,并有助于肠道免疫系统。乳铁蛋白补充剂已被报道可降低早产儿的败血症发生率。乳铁蛋白可能在降低败血症的发生率方面发挥作用,从而降低发病率和死亡率,并改善术后足月新生儿的肠内喂养。
本综述的主要目的是评估在接受胃肠道手术后的足月新生儿中给予乳铁蛋白对败血症发生率和死亡率的疗效。次要目的是评估在同一人群中给予乳铁蛋白对完全肠内喂养时间、肠道微生物群、住院时间和出院前死亡率的影响。
Cochrane 新生儿信息专家检索了 Cochrane 对照试验中心注册库(CENTRAL)、Ovid MEDLINE、Embase Ovid、CINAHL、世界卫生组织国际临床试验注册平台(ICTRP)和 ClinicalTrials.gov 试验注册库。最后一次检索日期为 2023 年 2 月。本研究对语言、出版年份或出版类型没有限制。我们检查了潜在相关研究和系统综述的参考文献。
我们计划纳入研究接受 37 周或以上胎龄、出生后 28 天内进行过一次或多次胃肠道手术的婴儿,并比较乳铁蛋白与安慰剂的给药。
我们使用标准的 Cochrane 方法学程序。我们计划使用 GRADE 方法评估每个结局的证据确定性。
我们没有发现评估乳铁蛋白对胃肠道手术后足月新生儿术后管理效果的已发表随机对照研究。
目前尚无随机对照试验的证据表明乳铁蛋白对胃肠道手术后足月新生儿的术后管理是否有效或无效。需要进行随机对照试验来评估乳铁蛋白在这种情况下的作用。